Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE: Bisoprolol Pharmacogenetics in Hypertension
NCT02398929Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2013
- Primary completion
- Jan 2021
- Countries
- 1
- Sponsor
- The Chinese University of Hong Kong
- Modality
- Orthosteric Ligands
- Drugs
- bisoprolol
- Conditions
- essential hypertension
01
Overview
Phase 4, open-label, single-arm trial of bisoprolol in essential hypertension, sponsored by The Chinese University of Hong Kong. Primary endpoint: Influence of ADRB1 polymorphisms on changes in sitting clinic blood pressure at 6 weeks. Started Jan 2013; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Bisoprolol 2.5 mg
Bisoprolol 2.5 mg daily
03
Endpoints
Primary
Influence of ADRB1 polymorphisms on changes in sitting clinic blood pressure
Secondary
Change of blood pressure from baseline by clinic sitting blood pressure according to other genotypes
Influence of ADRB1 polymorphisms on changes in ambulatory blood pressure
Beyond the preview
Go deeper on NCT02398929.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398929.